Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
LEXINGTON, Mass., April 24, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
